GlassScriptPhysician profile
Travis R Huffman
NPI 1982135703
$3,378.37
in general payments reported to CMS, 2019-2025
35 companies · $634 in 2025
The $634 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $160 · 2021: $308 · 2022: $805 · 2023: $696 · 2024: $775 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,004.50 |
| Education | $100.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $625.34 | 2021-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.58 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $237.25 | 2023-2025 | |
| Pfizer INC. | $208.36 | 2022-2025 | |
| Heartflow, INC. | $166.74 | 2025 | |
| Abbott Laboratories | $156.41 | 2023-2025 | Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Sanofi-Aventis U.S. LLC | $136.05 | 2021-2023 | |
| Boston Scientific Corporation | $130.22 | 2020-2022 | |
| Medtronic, INC. | $127.76 | 2024 | Ffrangio |
| E.R. Squibb & Sons, L.L.C. | $122.99 | 2024-2025 | Eliquis, Camzyos |
| Philips North America LLC | $107.37 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $97.54 | 2023 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $97.51 | 2020-2023 | Farxiga |
| Esperion Therapeutics, INC. | $91.26 | 2020-2025 | Nexletol |
| Scpharmaceuticals INC. | $87.14 | 2024-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $73.62 | 2022-2023 | Onpattro |
| Abiomed | $69.03 | 2025 | |
| Grifols USA, LLC | $55.97 | 2021-2023 | Prolastin-C Liquid |
| Terumo Medical Corporation | $53.00 | 2022 | |
| Mallinckrodt Hospital Products INC. | $51.96 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $47.04 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.40 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $38.42 | 2024 | Arcalyst |
| Livanova USA, INC. | $36.09 | 2022-2023 | Lifesparc |
| Merck Sharp & Dohme LLC | $34.91 | 2022-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $34.13 | 2024 | Xarelto |
| Baxter Healthcare | $30.19 | 2023 | Hillrom - Life 2000 Ventilation System |
| Smith+Nephew, INC. | $27.27 | 2025 | |
| Chiesi USA, INC. | $25.93 | 2021 | |
| Akcea Therapeutics, INC. | $25.59 | 2020 | |
| Exact Sciences Corporation | $22.61 | 2024 | Cologuard Collection Kit |
| Atricure, INC. | $21.89 | 2022 | |
| Altathera Pharmaceuticals LLC | $20.68 | 2023 | Sotalol Hydrochloride |
| Abbvie INC. | $13.98 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5.14 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Huffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.